Cambridge Nutritional Sciences (LSE:CNSL), the AIM-quoted diagnostics company, heads towards its Annual General Meeting later this month after final results for the year to 31 March 2026 showed falling revenue, a statutory loss and a lower cash balance. The company has since been the subject of shareholding notifications in late September, while management continues to point to Margin gains and a regulatory programme as foundations for recovery.
What the Company Does
Cambridge Nutritional Sciences describes itself as a specialist medical diagnostics Business focused on a personalised and functional approach to health and nutrition. It develops and manufactures diagnostic tests, including food sensitivity products, and sells them through distributors and partners across a number of international markets. The company is led by chief executive James Cooper, with Ajay Patel as finance director and Carolyn Rand as non-executive chair.
Latest Developments
In a trading update on 22 April 2026, the company said Revenue for the year would be around £7.0m, down from £8.3m, after reduced and delayed orders from the Middle East and Asia in the second half. It linked the shortfall to geopolitical instability and disrupted trade rather than the loss of local partners, and said underlying growth was about 11% once those regions were excluded, helped particularly by the UK and India.
Final results published on 8 September 2026 confirmed revenue of £7.0m, a decline of around 16%. In its results, the company recorded a statutory pre-tax loss of £4.4m, against a £1.6m profit a year earlier, and a loss after tax of £5.8m that included a £3.0m Goodwill impairment. A restructuring completed in March 2026 reduced UK full-time equivalent headcount to 58 from 76, and board members took a voluntary 10% salary cut.
The company subsequently updated its notice of AGM on 11 September, setting the meeting for 28 October 2026 in Littleport, Cambridgeshire, so that shareholders receive the required notice period. Holdings notifications followed on 22 and 23 September.
Financial Picture
Gross margin improved to 67.8% from 65.3%, which management attributed to Manufacturing efficiencies and cost control. Adjusted EBITDA swung to a loss of about £0.4m from a profit of a similar size, and cash and deposits fell to £2.6m from £4.9m. The directors adopted the Going Concern basis, and a reverse stress test in the results indicated that revenue and gross margin could each deteriorate by a further 15% before forecast cash ran out, after mitigating actions. No Dividend was reported. Recent market data showed the shares at around 1.55p, implying a Market Value of under £4m.
Sector and index Context
The company is among the smaller healthcare names in the FTSE AIM All Share Index. Diagnostics businesses in Europe face the EU In Vitro Diagnostic Regulation (IVDR), which requires products to be recertified under stricter rules. Cambridge Nutritional Sciences said it believes existing resources can fund its IVDR project, with completion expected in 2027.
Key Risks
Key risks include exposure to volatile export markets in the Middle East and Asia, a limited cash cushion, execution of the IVDR programme, and the need to show sustained sales growth to return to profitability. As a micro-cap stock, Liquidity in the shares may also be limited.
What to Watch Next
Shareholders will look to the AGM on 28 October for any trading commentary, signs of recovery in Middle Eastern and Asian orders, progress on IVDR certification and evidence that the reduced cost base is narrowing losses.






Please wait processing your request...